RESUMO
L-tryptophan has been utilized as a feed additive in animal nutrition to improve growth performance, as well as a dietary supplement to alleviate various emotional symptoms in humans. Despite its benefits, concerns regarding its safety arose following the outbreak of eosinophilia-myalgia syndrome (EMS) among individuals who consumed L-tryptophan. The causative material of EMS was determined to be not L-tryptophan itself, but rather L-tryptophan impurities resulting from a specific manufacturing process. To investigate the effect of L-tryptophan and its impurities on humans who consume meat products derived from animals that were fed L-tryptophan and its impurities, an animal study involving broiler chickens was conducted. The animals in test groups were fed diet containing 0.065%-0.073% of L-tryptophan for 27 days. This study aimed to observe the occurrence of toxicological or EMS-related symptoms and analyze the residues of L-tryptophan impurities in meat products. The results indicated that there was no evidence of adverse effects associated with the test substance in the investigated parameters. Furthermore, most of the consumed EMS-causing L-tryptophan impurities did not remain in the meat of broiler chickens. Thus, this study demonstrated the safety of L-tryptophan and some of its impurities as a feed additive.
Assuntos
Síndrome de Eosinofilia-Mialgia , Triptofano , Humanos , Animais , Triptofano/toxicidade , Galinhas , Dieta/veterinária , Suplementos Nutricionais/efeitos adversos , Ração Animal/toxicidade , Ração Animal/análiseRESUMO
L-tryptophan is one of the essential amino acids in humans and across the animal kingdom. It has been widely used as a feed additive for domestic animals and is also administered through dietary supplements in humans. Safety concerns have been raised however since a disease known as eosinophilia-myalgia syndrome (EMS) was reported to be related to L-tryptophan supplements. EMS is a rare condition characterized by inflammation in various organ systems including the muscles, skin, and lungs. Through several studies, it has been speculated that the six components generated during the process of L-tryptophan synthesis are related to the induction of EMS. In this review, we discuss the history of EMS and its controversial correlation with L-tryptophan use reported in several studies. Many in vitro and in vivo studies have been conducted to assess the putative correlation between impurities in L-tryptophan preparations and EMS, but no clear and convincing conclusions have been drawn so far.
Assuntos
Síndrome de Eosinofilia-Mialgia , Animais , Humanos , Triptofano/química , Músculos , Suplementos NutricionaisRESUMO
The eosinophilia-myalgia syndrome (EMS) outbreak that occurred in the USA and elsewhere in 1989 was caused by the ingestion of Showa Denko K.K. (SD) L-tryptophan (L-Trp). "Six compounds" detected in the L-Trp were reported as case-associated contaminants. Recently the final and most statistically significant contaminant, "Peak AAA" was structurally characterized. The "compound" was actually shown to be two structural isomers resulting from condensation reactions of L-Trp with fatty acids derived from the bacterial cell membrane. They were identified as the indole C-2 anteiso (AAA1-343) and linear (AAA2-343) aliphatic chain isomers. Based on those findings, we utilized a combination of on-line HPLC-electrospray ionization mass spectrometry (LC-MS), as well as both precursor and product ion tandem mass spectrometry (MS/MS) to facilitate identification of a homologous family of condensation products related to AAA1-343 and AAA2-343. We structurally characterized eight new AAA1-XXX/AAA2-XXX contaminants, where XXX represents the integer molecular ions of all the related homologs, differing by aliphatic chain length and isomer configuration. The contaminants were derived from the following fatty acids of the bacterial cell membrane, 5-methylheptanoic acid (anteiso-C8:0) for AAA1-315; n-octanoic acid (n-C8:0) for AAA2-315; 6-methyloctanoic acid (anteiso-C9:0) for AAA1-329; n-nonanoic acid (n-C9:0) for AAA2-329; 10-methyldodecanoic acid (anteiso-C13:0) for AAA1-385; n-tridecanoic acid (n-C13:0) for AAA2-385; 11-methyltridecanoic acid (anteiso-C14:0) for AAA1-399; and n-tetradecanoic acid (n-C14:0) for AAA2-399. The concentration levels for these contaminants were estimated to be 0.1-7.9⯵g / 500â¯mg of an individual SD L-Trp tablet or capsule The structural similarity of these homologs to case-related contaminants of Spanish Toxic Oil Syndrome (TOS) is discussed.
Assuntos
Suplementos Nutricionais/análise , Síndrome de Eosinofilia-Mialgia/induzido quimicamente , Ácidos Graxos/toxicidade , Contaminação de Alimentos , Indóis/toxicidade , Triptofano/análogos & derivados , Bacillus amyloliquefaciens/metabolismo , Caprilatos/análise , Caprilatos/química , Caprilatos/isolamento & purificação , Caprilatos/toxicidade , Centers for Disease Control and Prevention, U.S. , Cromatografia Líquida de Alta Pressão , Suplementos Nutricionais/efeitos adversos , Ácidos Graxos/análise , Ácidos Graxos/química , Ácidos Graxos/isolamento & purificação , Fermentação , Ácidos Heptanoicos/análise , Ácidos Heptanoicos/química , Ácidos Heptanoicos/isolamento & purificação , Ácidos Heptanoicos/toxicidade , Humanos , Indóis/análise , Indóis/química , Indóis/isolamento & purificação , Ácidos Láuricos/análise , Ácidos Láuricos/química , Ácidos Láuricos/isolamento & purificação , Ácidos Láuricos/toxicidade , Metilação , Estrutura Molecular , Miristatos/análise , Miristatos/química , Miristatos/isolamento & purificação , Miristatos/toxicidade , Espectrometria de Massas por Ionização por Electrospray , Estereoisomerismo , Triptofano/análise , Triptofano/química , Triptofano/isolamento & purificação , Estados UnidosRESUMO
The eosinophilia-myalgia syndrome (EMS) outbreak of 1989 that occurred in the USA and elsewhere was caused by the ingestion of l-Tryptophan (L-Trp) solely manufactured by the Japanese company Showa Denko K.K. (SD). Six compounds present in the SD L-Trp were reported to be case-associated contaminants. However, "one" of these compounds, Peak AAA has remained structurally uncharacterized, despite the fact that it was described as "the only statistically significant (p=0.0014) contaminant". Here, we employ on-line microcapillary-high performance liquid chromatography-electrospray ionization mass spectrometry (LC-MS), and tandem mass spectrometry (MS/MS) to determine that Peak AAA is in fact two structurally related isomers. Peak AAA1 and Peak AAA2 differed in LC retention times, and were determined by accurate mass-LC-MS to both have a protonated molecular ion (MH+) of mass 343.239Da (Da), corresponding to a molecular formula of C21H30N2O2, and possessing eight degrees of unsaturation (DoU) for the non-protonated molecule. By comparing the LC-MS and LC-MS-MS retention times and spectra with authentic synthetic standards, Peak AAA1 was identified as the intermolecular condensation product of L-Trp with anteiso 7-methylnonanoic acid, to afford (S)-2-amino-3-(2-((S,E)-7-methylnon-1-en-1-yl)-1H-indol-3-yl)propanoic acid. Peak AAA2 was determined to be a condensation product of L-Trp with decanoic acid, which produced (S)-2-amino-3-(2-((E)-dec-1-en-1-yl)-1H-indol-3-yl)propanoic acid.
Assuntos
Contaminação de Medicamentos , Síndrome de Eosinofilia-Mialgia/induzido quimicamente , Triptofano/análogos & derivados , Triptofano/química , Cromatografia Líquida de Alta Pressão , Suplementos Nutricionais , Humanos , Espectrometria de Massas , Espectrometria de Massas em Tandem , Triptofano/efeitos adversos , Triptofano/isolamento & purificaçãoRESUMO
The daily nutritional requirement for L-tryptophan (Trp) is modest (5 mg/kg). However, many adults choose to consume much more, up to 4-5 g/d (60-70 mg/kg), typically to improve mood or sleep. Ingesting L-Trp raises brain tryptophan levels and stimulates its conversion to serotonin in neurons, which is thought to mediate its actions. Are there side effects from Trp supplementation? Some consider drowsiness a side effect, but not those who use it to improve sleep. Though the literature is thin, occasional side effects, seen mainly at higher doses (70-200 mg/kg), include tremor, nausea, and dizziness, and may occur when Trp is taken alone or with a drug that enhances serotonin function (e.g., antidepressants). In rare cases, the "serotonin syndrome" occurs, the result of too much serotonin stimulation when Trp is combined with serotonin drugs. Symptoms include delirium, myoclonus, hyperthermia, and coma. In 1989 a new syndrome appeared, dubbed eosinophilia myalgia syndrome (EMS), and was quickly linked to supplemental Trp use. Key symptoms included debilitating myalgia (muscle pain) and a high peripheral eosinophil count. The cause was shown not to be Trp but a contaminant in certain production batches. This is not surprising, because side effects long associated with Trp use were not those associated with the EMS. Over 5 decades, Trp has been taken as a supplement and as an adjunct to medications with occasional modest, short-lived side effects. Still, the database is small and largely anecdotal. A thorough, dose-related assessment of side effects remains to be conducted.
Assuntos
Triptofano/efeitos adversos , Afeto/efeitos dos fármacos , Suplementos Nutricionais , Síndrome de Eosinofilia-Mialgia/induzido quimicamente , Humanos , Serotonina/biossíntese , Sono/efeitos dos fármacos , Triptofano/metabolismoRESUMO
The aryl-hydrocarbon-receptor (AHR) is involved as receptor and transcription factor in dioxin toxicity. Recently, its role in Th17-mediated autoimmunity and autoinflammation has been described, yet a disease-associated AHR ligand is still elusive. L-tryptophan and its metabolites are assumed to trigger the autoinflammatory disorders eosinophilic fasciitis, eosinophilia-myalgia-syndrome and toxic oil syndrome. Since L-tryptophan and metabolites are well known as AHR ligands we hypothesize that it is their interaction with AHR that induces Th17 cell differentiation and autoinflammation in these disorders. This, for the first time would link disease-causing environmental factors to a well-defined cellular receptor and the subsequent pathogenic pathway.
Assuntos
Síndrome de Eosinofilia-Mialgia/etiologia , Eosinofilia/etiologia , Fasciite/etiologia , Inflamação/etiologia , Interleucina-17/metabolismo , Receptores de Hidrocarboneto Arílico/metabolismo , Triptofano/metabolismo , Brassica/química , Fasciite/imunologia , Fasciite/fisiopatologia , Ácidos Graxos Monoinsaturados , Humanos , Inflamação/imunologia , Inflamação/fisiopatologia , Óleos de Plantas/toxicidade , Óleo de Brassica napus , Síndrome , Linfócitos T Auxiliares-Indutores/citologia , Linfócitos T Auxiliares-Indutores/imunologia , Linfócitos T Auxiliares-Indutores/metabolismoAssuntos
Benzofuranos/toxicidade , Edema/etiologia , Síndrome de Eosinofilia-Mialgia/etiologia , Contaminação de Alimentos , Doenças Transmitidas por Alimentos/etiologia , Óleos de Plantas/toxicidade , Bifenilos Policlorados/toxicidade , Bacillus , Benzofenantridinas/sangue , Biomarcadores/sangue , Dibenzofuranos Policlorados , Edema/induzido quimicamente , Edema/diagnóstico , Edema/história , Edema/microbiologia , Edema/terapia , Síndrome de Eosinofilia-Mialgia/induzido quimicamente , Síndrome de Eosinofilia-Mialgia/diagnóstico , Síndrome de Eosinofilia-Mialgia/história , Síndrome de Eosinofilia-Mialgia/microbiologia , Síndrome de Eosinofilia-Mialgia/terapia , Manipulação de Alimentos/métodos , História do Século XX , Humanos , Isoquinolinas/sangue , Mostardeira/toxicidade , Oryza , Fatores de RiscoAssuntos
Síndrome de Eosinofilia-Mialgia/etiologia , Contaminação de Alimentos , Óleos de Plantas/intoxicação , Triptofano/efeitos adversos , Compostos de Anilina , Animais , Surtos de Doenças , Síndrome de Eosinofilia-Mialgia/epidemiologia , Ácidos Graxos Monoinsaturados , Feminino , Humanos , Masculino , Propilenoglicóis , Óleo de Brassica napus , Síndrome , Fatores de TempoRESUMO
Eosinophilia-myalgia syndrome (EMS) was an intoxication episode that occurred in the US in 1989 and affected 1,500 people. EMS was associated with the ingestion of manufactured L-tryptophan, and 3-(N-phenylamino)alanine (PAA) was identified as one of the contaminants present in the L-tryptophan batches responsible for intoxication. In previous studies (Martínez-Cabot et al., Chem Res. Toxicol., in press), we have shown that the incubation of 3-(N-phenylamino)propane-1,2-diol (PAP), a toxic biomarker of the oil batches that caused Toxic Oil Syndrome in Spain, with human liver microsomes generates a reactive quinoneimine intermediate. The structural similarity between PAA and PAP led Mayeno and co-workers (Mayeno et al. (1995) Chem. Res. Toxicol. 8, 911-916) to hypothesize that both xenobiotics could be linked to a common etiologic agent. We thus set about to study the bioactivation of PAA by human liver microsomes. Under these conditions, PAA is converted to its 4'-hydroxy derivative, an unstable intermediate that is rapidly transformed into the final metabolites 4-aminophenol and formylglycine, which were identified in the incubations by GC/MS using the H2(18)O-labeled medium. We also provide evidence that 4-aminophenol and formylglycine are formed from a quinoneimine intermediate via a pathway similar to that demonstrated for PAP bioactivation. This quinoneimine, in the absence of nucleophiles in the incubation medium, could isomerize to give the corresponding imine, which could undergo hydrolysis to yield the aforementioned final products. These findings establish that EMS and TOS are linked by a common toxic metabolite (4-aminophenol) and that they may be further linked by the concomitant release of potentially hazardous carbonyl species.
Assuntos
Alanina/análogos & derivados , Síndrome de Eosinofilia-Mialgia/metabolismo , Contaminação de Alimentos , Doenças Transmitidas por Alimentos/metabolismo , Microssomos Hepáticos/metabolismo , Óleos de Plantas/toxicidade , Quinonas/metabolismo , Triptofano/toxicidade , Alanina/metabolismo , Alanina/toxicidade , Biotransformação , Cromatografia Líquida de Alta Pressão , Surtos de Doenças , Síndrome de Eosinofilia-Mialgia/etiologia , Ácidos Graxos Monoinsaturados , Doenças Transmitidas por Alimentos/etiologia , Humanos , Microssomos Hepáticos/efeitos dos fármacos , Óleo de Brassica napus , Espanha , Espectrometria de Massas por Ionização por ElectrosprayRESUMO
Most attempts to reproduce the toxic oil syndrome in animals, either with case-related oils or with refined rapeseed oils, have been unsuccessful. An aniline-denatured rapeseed oil that was subsequently refined according to a protocol yielding relevant markers of "toxic oil" (oil RSO160401) had led to possibly relevant lesions following oral administration in mice. Therefore, in the present study, RSO160401 was subjected to a more extended in vivo testing. To try and maximize the response, BALB/c, DBA/2, A/J, and C57BL/6 mice were administered RSO160401 oil by a single intra-tracheal instillation (1ml/kg), with sacrifice 2 or 7 days post-exposure. Intra-tracheal administration led to a strain-dependent acute response: acute pulmonary damage in DBA/2 and A/J mice, and increases in blood eosinophilia in DBA/2 mice (6.5% vs 3.1% in controls). The pulmonary lesions regressed with time after exposure, being more complete in A/J than in DBA/2 mice. The observation of strain-dependent effects suggests that genetic susceptibility is an important factor in disease induction by the RSO160401 oil.
Assuntos
Compostos de Anilina/toxicidade , Modelos Animais de Doenças , Síndrome de Eosinofilia-Mialgia/diagnóstico , Camundongos Endogâmicos/classificação , Óleos de Plantas/toxicidade , Síndrome do Desconforto Respiratório/diagnóstico , Compostos de Anilina/administração & dosagem , Animais , Síndrome de Eosinofilia-Mialgia/induzido quimicamente , Ácidos Graxos Monoinsaturados , Feminino , Humanos , Camundongos , Óleos de Plantas/administração & dosagem , Óleo de Brassica napus , Síndrome do Desconforto Respiratório/induzido quimicamente , TraqueiaRESUMO
In contrast to early epidemiological evidence offering links between eosinophilia-myalgia syndrome (EMS) and microimpurities of L-tryptophan-containing dietary supplements (LTCDS), this account shows why reliance on a finite impurity from one manufacturer is both unnecessary and insufficient to explain the etiology of EMS. Excessive histamine activity has induced blood eosinophilia and myalgia (Greek: mys, muscle + algos, pain). Termination of the multiple actions of histamine is dependent on particular amine oxidases and histamine-N-methyltransferase. Histamine metabolism is rapid when these degradative reactions are operative. The latent effects of incurred histamine can be potentiated and aggravating when these mechanisms are impaired. Overloads of tryptophan supplements cause - among other relevant side-effects - an increased formation of formate and indolyl metabolites, several of which inhibit the degradation of histamine. Moreover, (non-EMS) subjects with hypothalamic-pituitary- adrenal (HPA) axis dysregulation have also manifested greatly increased sensitivities to incurred tryptophan and histamine. A final common pathway for syndromes characterized by eosinophilia with myalgia is now evident.
Assuntos
Síndrome de Eosinofilia-Mialgia/metabolismo , Histamina/metabolismo , Aminoácidos/metabolismo , Aminoácidos/toxicidade , Animais , Síndrome de Eosinofilia-Mialgia/induzido quimicamente , Humanos , Sistema Hipotálamo-Hipofisário/efeitos dos fármacos , Indóis/metabolismo , Mastócitos/metabolismo , Serotonina/metabolismo , Triptofano/metabolismo , Triptofano/toxicidadeRESUMO
BACKGROUND AND OBJECTIVE: In 1981, toxic oil syndrome (TOS) appeared in Spain, affecting more than 20,000 persons and causing over 2500 deaths to date. Previous studies have addressed mortality only by gender and age. We analyzed possible prognostic factors in the survival of the cohort. METHODS: The study period was 1 May 1981 to 31 December 1995 (31 December 1995 was the cut-off date for survivors). The study population consisted of the entire cohort. Overall mortality and TOS-related deaths were studied. Kaplan-Meier method and Cox regression were used in the analyses. RESULTS: Among the 20,084 subjects in the cohort, 12,164 (60.6%) were women, and 7917 (39.4%) were men. Of the 1799 deaths, 958 (53.3%) were women, and 841 (46.71%) were men; of the 356 TOS-related deaths, 234 (65.7%) were women, and 122 (34.3%) were men. TOS was the leading cause of death among subjects <40 years of age. Among the TOS-related deaths, the shortest survival times were for women and subjects <40 years of age. The major disease manifestations had the highest relative risks (RR) (liver disease, RR 3.83; pulmonary infection, RR 1.54; motor neuropathy, RR 2.24; pulmonary hypertension, RR 3.19; and eosinophilia, RR 1.14.). CONCLUSIONS: The major clinical manifestations showed worse prognosis for overall and TOS-related mortality. Application of these results to the survivors will help clarify the validity of these conclusions.
Assuntos
Síndrome de Eosinofilia-Mialgia/mortalidade , Contaminação de Alimentos , Óleos de Plantas/intoxicação , Adulto , Distribuição por Idade , Idoso , Brassica rapa/intoxicação , Causas de Morte , Estudos de Coortes , Síndrome de Eosinofilia-Mialgia/induzido quimicamente , Ácidos Graxos Monoinsaturados , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Prognóstico , Modelos de Riscos Proporcionais , Óleo de Brassica napus , Fatores de Risco , Distribuição por Sexo , Fatores Sexuais , Espanha/epidemiologia , Análise de SobrevidaRESUMO
Several distinct entities associated with dermal fibrosis can mimic scleroderma/systemic sclerosis. The list of scleroderma-like conditions or scleroderma variants includes eosinophilic fasciitis, localized forms of scleroderma, scleredema and scleromyxedema, keloids, and environmental exposure-associated conditions including eosinophilia-myalgia syndrome and pseudosclerodermas induced by various drugs. Although these conditions are relatively uncommon, their accurate recognition is essential to avoid misdiagnosis and inappropriate therapy. The pathogenesis of these scleroderma variants appears to share similarities with each other and with that of scleroderma. Better understanding of scleroderma-like disorders is emerging through epidemiologic investigations, and in vivo and in vitro experimental research. Activation of eosinophils and disordered regulation of fibroblast collagen synthesis, apoptosis, and proliferation are recurrent findings in these disorders. The etiologic role of infection with Borrelia species or other microorganisms remains controversial. Cytokines such as transforming growth factor-beta, interleukin-4, interleukin-13, and connective tissue growth factor contribute to fibrosis in these disorders by inducing an accentuated and persistent fibrogenic response to tissue injury. The role of genetic factors in susceptibility and clinical expression of scleroderma-like conditions remains to be systematically addressed. Because of the relative rarity of these conditions, few well-controlled clinical treatment trials have been performed. In addition, there is no consensus on optimal management. Much anecdotal information and small clinical series indicate that phototherapy may have a role in the treatment of scleroderma-like conditions.
Assuntos
Esclerodermia Localizada , Escleroderma Sistêmico , Dermatopatias , Diagnóstico Diferencial , Síndrome de Eosinofilia-Mialgia/diagnóstico , Síndrome de Eosinofilia-Mialgia/terapia , Fasciite/diagnóstico , Fasciite/terapia , Humanos , Esclerodermia Localizada/diagnóstico , Esclerodermia Localizada/terapia , Escleroderma Sistêmico/diagnóstico , Escleroderma Sistêmico/terapia , Dermatopatias/diagnóstico , Dermatopatias/terapia , SíndromeRESUMO
Eosinophilia-myalgia syndrome(EMS) is a systemic illness that occurred as an epidemic by ingestion of over-the counter L-tryptophan preparation in the United States in October 1989. We report a Korean case of EMS not associated with the ingestion of either L-tryptophan or other nutritional supplements such as lysine and niacin.
Assuntos
Ingestão de Alimentos , Síndrome de Eosinofilia-Mialgia , Lisina , Niacina , Triptofano , Estados UnidosAssuntos
Síndrome de Eosinofilia-Mialgia/etiologia , Fasciite/etiologia , Contaminação de Alimentos , Miosite/etiologia , Doenças Vasculares Periféricas/etiologia , Óleos de Plantas/efeitos adversos , Propilenoglicóis/intoxicação , Triptofano/efeitos adversos , Diagnóstico Diferencial , Ácidos Graxos Monoinsaturados , Humanos , Pneumonia/etiologia , Prognóstico , Óleo de Brassica napus , SíndromeRESUMO
With hindsight, it is easy to criticise the standards of food regulation of two decades ago. Nevertheless, when the Spanish toxic oil syndrome (TOS) appeared in 1981, there were many who asked why aniline was permitted as an official adulterant for imported French rape seed oil, and why such adulterated oils were often illegally refined in Spain and marketed without difficulty. This review brings up to date a comprehensive survey of the ensuing research published in 1995 and concentrates on recent significant findings. These include the identification of the refinery that produced the toxic oil, and the detection of oil contaminants with possible aetiological significance. Possible chemical links have been found between oil contaminants and those detected in L-tryptophan implicated in the eosinophilia-myalgia syndrome (EMS). There is good evidence that the initial pathogenetic mechanism is immunological. On metabolic evidence, it is suggested that not one, but a group of, toxic agents was responsible for TOS.
Assuntos
Compostos de Anilina/intoxicação , Gorduras Insaturadas na Dieta/intoxicação , Síndrome de Eosinofilia-Mialgia/etiologia , Contaminação de Alimentos/análise , Transtornos Respiratórios/etiologia , Surtos de Doenças , Síndrome de Eosinofilia-Mialgia/epidemiologia , Síndrome de Eosinofilia-Mialgia/imunologia , Ácidos Graxos Monoinsaturados , Humanos , Óleos de Plantas/química , Óleos de Plantas/intoxicação , Óleo de Brassica napus , Transtornos Respiratórios/epidemiologia , Transtornos Respiratórios/imunologia , Espanha/epidemiologiaRESUMO
Recently, 5-hydroxy-L-tryptophan (5-OHTrp) has been promoted as an alternative to banned L-tryptophan as a dietary supplement. It has been claimed to help alleviate obesity, insomnia, depression, and headaches. However, eosinophilia-myalgia syndrome (EMS)-like symptoms have also been associated with ingestion or exposure to 5-OHTrp. HPLC-UV analysis of EMS-implicated 5-OHTrp revealed the presence of peak X, described as case-implicated. We show that peak X is actually a family of contaminants with the same molecular weight (234 Da) and similar HPLC retention times. We also demonstrate that all eight samples of commercially available 5-OHTrp analyzed by HPLC-MS contained three or more contaminants of the peak X family. The significance of these findings is discussed.
Assuntos
5-Hidroxitriptofano/efeitos adversos , 5-Hidroxitriptofano/química , Contaminação de Medicamentos , Síndrome de Eosinofilia-Mialgia/induzido quimicamente , 5-Hidroxitriptofano/normas , Cromatografia Líquida de Alta Pressão , Suplementos Nutricionais/efeitos adversos , Humanos , Espectrometria de Massas , Reprodutibilidade dos TestesRESUMO
In 1981 a massive food-borne epidemic, termed the toxic oil syndrome (TOS), occurred in Spain. Eight years later a closely related disease, the eosinophilia myalgia syndrome (EMS), was reported in the USA with many additional cases being reported worldwide. Although EMS was linked to the ingestion of contaminated L-tryptophan and TOS to aniline denatured rapeseed oil, the etiological agent(s) responsible for both diseases remains unknown. However, contaminants in both the oil and the dietary supplement are believed to have triggered these diseases, and there has been much speculation that a common contaminant may have caused both epidemics. In this report, methods for the facile preparation and HPLC analysis of EMS-implicated L-tryptophan and adulterated rapeseed oil samples associated with TOS are described which allow a direct comparison between the contaminants of both foodstuffs. A combination of solvent and solid phase extraction methods are demonstrated along with the application of C18 reversed-phase high-performance liquid chromatography (RP-HPLC) coupled with on-line UV and MS detection. These methods have allowed us to determine for the first time, based upon this work, that there are no detectable common contaminants that possess a UV response, between EMS implicated L-tryptophan and TOS implicated rapeseed oil samples.
Assuntos
Cromatografia Líquida de Alta Pressão/métodos , Síndrome de Eosinofilia-Mialgia/induzido quimicamente , Contaminação de Alimentos , Óleos de Plantas/química , Triptofano/química , Ácidos Graxos Monoinsaturados , Humanos , Espectrometria de Massas , Óleos de Plantas/efeitos adversos , Óleo de Brassica napus , Espectrofotometria Ultravioleta , Triptofano/efeitos adversosRESUMO
On-line HPLC/electrospray ionization-tandem mass spectrometry (LC/ESI-MS/MS) in conjunction with NMR has been successfully employed to identify and structurally characterize seven contaminants found in three different commercial preparations of melatonin. Six of these contaminants were identified as analogues of impurities found in contaminated L-tryptophan (an over-the-counter dietary supplement) associated with the eosinophilia-myalgia syndrome (EMS) epidemic that occurred in the United States during 1989. In particular, our studies identified two compounds with MH+ = 249 to be hydroxymelatonin isomers. Four other compounds with MH+ = 477 were identified as melatonin-formaldehyde condensation products. These compounds are structural analogues of L-tryptophan contaminants, namely, 'peak C' and 'peak E' that were previously implicated as etiological agents causing EMS. It has been reported that melatonin consumption has resulted in eosinophilia in some humans taking high doses of this supplement. Although there has not been a major outbreak of EMS-like symptoms from consumption of melatonin, this study clearly suggests that tighter control and regulation of nutritional supplements sold and used as drugs is necessary.
Assuntos
Contaminação de Medicamentos , Melatonina/química , Triptofano/química , Cromatografia Líquida de Alta Pressão , Surtos de Doenças , Síndrome de Eosinofilia-Mialgia/induzido quimicamente , Síndrome de Eosinofilia-Mialgia/epidemiologia , Formaldeído/química , Humanos , Espectrometria de Massas , Estrutura Molecular , Triptofano/efeitos adversos , Estados Unidos/epidemiologiaRESUMO
OBJECTIVE: To explore whether antiphospholipid antibodies (aPL) are markers of vascular related damage or merely evidence of toxic related autoimmunity, we investigated the presence of different aPL in patients with toxic oil syndrome (TOS) and compared the profile with patients with eosinophilia myalgia syndrome (EMS). METHODS: Reactivity against cardiolipin, P-serine, P-inositol, and P-choline was investigated by ELISA in the blood of 266 patients with acute and chronic TOS, 25 healthy relatives of TOS patients, and 48 patients with EMS. RESULTS: 32% of TOS and 13% of EMS patients had IgG antibodies against cardiolipin and other polyanions. 20% of both TOS and EMS patients presented IgM antibodies against anionic and zwitterionic phospholipids. 36% of TOS healthy relatives had IgM antibodies against differently charged phospholipids. Among 200 patients with chronic TOS, there was no significant association between antibodies and clinical manifestations. CONCLUSION: aPL with different specificity are present in a high percentage of patients with TOS and EMS. The significance of these antibodies remains unclear.